Precision Oncology Diagnostics Built for Institutional Excellence
Silver Gene Laboratories elevates institutional oncology standards by delivering targeted genomic insights that support clinical teams in the personalization of cancer care.
We empower healthcare networks to proactively reduce severe treatment-related adverse reactions, support informed therapeutic decision-making, and preserve continuity of care while driving measurable health economic value and prioritizing patient safety.
Our high-complexity, CLIA-certified and CAP-accredited laboratory translates complex genomic data into clear, CPIC-compliant insights for critical pathways—including DPYD for fluoropyrimidines and UGT1A1 for irinotecan. Engineered to minimize Grade 3–4 toxicities, our concise reports provide busy oncology teams with definitive, time-sensitive support when every clinical decision counts.
Clinical Utility & Guideline-Driven Impact
Systemic chemotherapy agents possess exceptionally narrow therapeutic windows. Inherited genetic polymorphisms within critical drug-metabolizing enzymes, cellular transporters, and toxicity pathways introduce profound variability in drug clearance, escalating the risk of severe, life-threatening Adverse Drug Reactions (ADRs) or driving therapeutic failure.
Evidence-Based Decision Support
The Silver PGx Oncology Panel delivers targeted, high-density pharmacogenomic data directly mapped to established CPIC (Clinical Pharmacogenetics Implementation Consortium) and PharmGKB clinical guidelines. By screening for validated, high-penetrance variants before treatment initiation, the panel provides oncology teams with the objective metabolic metrics required to inform therapeutic selection, guide baseline dosage adjustments, or implement alternative regimens—proactively reducing preventable toxicities while preserving anti-tumor efficacy.
Ready to bring precision oncology diagnostics to your clinical network?
The Silver PGx Oncology Panel delivers targeted, clinically validated pharmacogenomic insights that support clinical teams in mitigating severe toxicities, guiding baseline adjustments, and making evidence-based therapeutic choices when every decision counts.
Proven Clinical Value
Peer-Reviewed Evidence of Improved Outcomes in Oncology
Mitigating Severe Fluoropyrimidine Toxicity Risks
Up to 30% of patients treated with fluoropyrimidines—such as 5-fluorouracil (5-FU) and capecitabine—experience severe, potentially life-threatening Grade 3–4 toxicities.
Prospective, upfront DPYD genotyping paired with guided dosing protocols substantially mitigates this clinical risk. Peer-reviewed data demonstrates that pre-treatment screening reduces the incidence of severe adverse drug reactions (ADRs) by approximately 30%, normalizing toxicity rates in metabolic variant carriers to levels comparable with wild-type (DPYD normal-function) populations.
For the Lau Study: [View Peer-Reviewed Data: Lau et al., BMC Cancer, 2023]
For the Nguyen Study: [Access Clinical Publication: Nguyen et al., JCO Precision Oncology, 2024]
Decreasing Total Toxicity & Maximizing Treatment Tolerance
Approximately 60% of patients diagnosed with advanced solid tumors are prescribed therapeutic regimens with established CPIC pharmacogenetic guidelines.
Data from a landmark, multi-center randomized controlled trial demonstrates that utilizing a multi-gene PGx panel to prospectively guide systemic therapy reduces the incidence of clinically relevant, treatment-induced adverse drug reactions (ADRs) by approximately 30%. This proactive approach directly translates to enhanced treatment tolerance, a significant reduction in toxicities, and fewer unplanned dose modifications or cycle interruptions, thereby preserving therapeutic continuity.
Driving Quantifiable Cost-Avoidance & Clinical Optimization
Prospective PGx testing inherently aligns clinical optimization with health economic value. Real-world utilization data tracks profound cost-avoidance metrics: a U.S. study of gastrointestinal (GI) cancer patients evaluating upfront DPYD-guided dosing recorded zero hospitalizations for severe toxicities—compared to six costly admissions in the un-screened cohort.
This proactive protocol delivered an average net savings of $2,356 per patient, validating peer-reviewed evidence (JCO Precision Oncology, 2024) that pre-treatment genotyping protects hospital resources while establishing a superior standard of care.
For the ASCO 2026 Abstract:
For the JCO Publication: